2022
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
Dohm A, Tang J, Mills M, Liveringhouse C, Sandoval M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. Journal Of Neurosurgery 2022, 138: 1600-1607. PMID: 36681988, DOI: 10.3171/2022.9.jns221896.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesCancer brain metastasesSystemic therapyBrain metastasesStereotactic radiosurgeryCheckpoint inhibitorsLocal controlGrowth factor receptor tyrosine kinase inhibitorsSingle-fraction stereotactic radiosurgeryReceptor tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsKinase inhibitorsChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesTyrosine kinase inhibitorsBM diagnosisIntracranial controlBM patientsOverall survivalUpfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Yu H, Oliver D, Ahmed K. Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e14. DOI: 10.1016/j.ijrobp.2021.10.186.Peer-Reviewed Original ResearchDistant intracranial controlEGFR-positive NSCLCBrain metastasesRadiation therapyBM diagnosisOverall survivalLocal controlMultivariate analysisSingle-institution retrospective analysisGeneration tyrosine kinase inhibitorsCentral nervous system penetrationUpfront radiation therapyKaplan-Meier methodProportional hazards modelTyrosine kinase inhibitorsMATERIAL/METHODSIntracranial radiation therapyIntracranial controlUpfront treatmentDS-GPAClinical outcomesResults MedianRetrospective analysisTreatment groupsHazards model
2012
Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer
Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal 2012, 18: 345-350. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.Peer-Reviewed Original ResearchConceptsBrain metastasesOverall survivalBreast cancerDiagnosis of BMIncidence of BMMedian age 53 yearsRisk of BMTriple-negative breast cancerActuarial median survivalLimited overall survivalAge 53 yearsGroup of patientsPatterns of recurrenceSingle-institution studyNegative breast cancerElectronic medical recordsBM diagnosisMedian survivalMetastatic diseaseEntire cohortRetrospective studyTherapeutic optionsInstitutional databaseMedical recordsModern therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply